Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharm Stat. 2014 Jul-Aug;13(4):229-37. doi: 10.1002/pst.1622. Epub 2014 May 29.

When is a seamless study desirable? Case studies from different pharmaceutical sponsors.

Author information

1
ViiV Healthcare, Middlesex, UK.

Abstract

BACKGROUND:

Inferentially seamless studies are one of the best-known adaptive trial designs. Statistical inference for these studies is a well-studied problem. Regulatory guidance suggests that statistical issues associated with study conduct are not as well understood. Some of these issues are caused by the need for early pre-specification of the phase III design and the absence of sponsor access to unblinded data. Before statisticians decide to choose a seamless IIb/III design for their programme, they should consider whether these pitfalls will be an issue for their programme.

METHODS:

We consider four case studies. Each design met with varying degrees of success. We explore the reasons for this variation to identify characteristics of drug development programmes that lend themselves well to inferentially seamless trials and other characteristics that warn of difficulties.

RESULTS:

Seamless studies require increased upfront investment and planning to enable the phase III design to be specified at the outset of phase II. Pivotal, inferentially seamless studies are unlikely to allow meaningful sponsor access to unblinded data before study completion. This limits a sponsor's ability to reflect new information in the phase III portion.

CONCLUSIONS:

When few clinical data have been gathered about a drug, phase II data will answer many unresolved questions. Committing to phase III plans and study designs before phase II begins introduces extra risk to drug development. However, seamless pivotal studies may be an attractive option when the clinical setting and development programme allow, for example, when revisiting dose selection.

KEYWORDS:

adaptive; clinical trial; design; seamless

PMID:
24891148
DOI:
10.1002/pst.1622
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center